Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,511.50 GBX | -2.45% |
|
-0.10% | +12.25% |
Jun. 13 | Alector, Inc. Announces Chief Financial Officer Changes | CI |
Jun. 13 | Moderna falls on doubts over new CDC panel's backing of RSV vaccine | RE |
Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 6.62 | 6.24 | 6.57 | 8.82 | 6.52 | |||||
Return on Total Capital | 10.95 | 10.65 | 11.95 | 16.97 | 12.7 | |||||
Return On Equity % | 32.62 | 24.18 | 31.31 | 46.38 | 22.8 | |||||
Return on Common Equity | 44.24 | 29.59 | 34.78 | 41.16 | 19.06 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 68.06 | 66.42 | 67.92 | 72.34 | 71.81 | |||||
SG&A Margin | 30.8 | 29.87 | 27.89 | 30.19 | 34.59 | |||||
EBITDA Margin % | 30.41 | 29.04 | 32.29 | 33.98 | 26.49 | |||||
EBITA Margin % | 27.51 | 26.16 | 28.67 | 31.03 | 23.67 | |||||
EBIT Margin % | 24.88 | 23.35 | 24.97 | 27.71 | 19.71 | |||||
Income From Continuing Operations Margin % | 18.73 | 14.94 | 16.78 | 17.5 | 9.41 | |||||
Net Income Margin % | 16.86 | 12.85 | 51 | 16.25 | 8.21 | |||||
Net Avail. For Common Margin % | 16.86 | 12.85 | 15.21 | 16.25 | 8.21 | |||||
Normalized Net Income Margin | 12.19 | 11.19 | 12.32 | 14.66 | 10.03 | |||||
Levered Free Cash Flow Margin | 23.6 | 18.96 | 16.88 | 11.75 | 15.63 | |||||
Unlevered Free Cash Flow Margin | 25.18 | 20.38 | 18.62 | 13.21 | 16.85 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.43 | 0.43 | 0.42 | 0.51 | 0.53 | |||||
Fixed Assets Turnover | 3.06 | 3.15 | 2.89 | 3.1 | 3.13 | |||||
Receivables Turnover (Average Receivables) | 6.18 | 5.78 | 5.01 | 5.34 | 5.47 | |||||
Inventory Turnover (Average Inventory) | 1.82 | 1.94 | 1.72 | 1.58 | 1.58 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.91 | 0.79 | 0.91 | 0.88 | 0.78 | |||||
Quick Ratio | 0.62 | 0.52 | 0.66 | 0.6 | 0.5 | |||||
Operating Cash Flow to Current Liabilities | 0.38 | 0.34 | 0.32 | 0.32 | 0.3 | |||||
Days Sales Outstanding (Average Receivables) | 59.23 | 63.1 | 72.8 | 68.34 | 66.89 | |||||
Days Outstanding Inventory (Average Inventory) | 200.7 | 187.68 | 212.03 | 231.58 | 231.04 | |||||
Average Days Payable Outstanding | 142.21 | 144.36 | 174.82 | 158.34 | 145.73 | |||||
Cash Conversion Cycle (Average Days) | 117.71 | 106.41 | 110.01 | 141.58 | 152.19 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 130.48 | 113.27 | 207.87 | 140.82 | 129.8 | |||||
Total Debt / Total Capital | 56.61 | 53.11 | 67.52 | 58.48 | 56.48 | |||||
LT Debt/Equity | 112.58 | 96.4 | 168.73 | 118.84 | 111.85 | |||||
Long-Term Debt / Total Capital | 48.84 | 45.2 | 54.8 | 49.35 | 48.67 | |||||
Total Liabilities / Total Assets | 74.13 | 73.02 | 83.21 | 78.32 | 77.99 | |||||
EBIT / Interest Expense | 9.86 | 10.28 | 8.94 | 11.84 | 10.06 | |||||
EBITDA / Interest Expense | 12.32 | 13.06 | 11.56 | 14.78 | 13.86 | |||||
(EBITDA - Capex) / Interest Expense | 10.89 | 11.54 | 10.17 | 12.93 | 11.59 | |||||
Total Debt / EBITDA | 2.56 | 2.39 | 2.22 | 1.72 | 1.99 | |||||
Net Debt / EBITDA | 1.92 | 1.9 | 1.29 | 1.17 | 1.49 | |||||
Total Debt / (EBITDA - Capex) | 2.9 | 2.7 | 2.52 | 1.96 | 2.38 | |||||
Net Debt / (EBITDA - Capex) | 2.17 | 2.15 | 1.47 | 1.34 | 1.78 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 1.02 | 0.04 | 18.74 | 3.42 | 3.46 | |||||
Gross Profit, 1 Yr. Growth % | 1.08 | -2.37 | 19.53 | 10.16 | 2.69 | |||||
EBITDA, 1 Yr. Growth % | -0.79 | -4.47 | 22.09 | 13.37 | -19.32 | |||||
EBITA, 1 Yr. Growth % | -0.58 | -4.86 | 25.08 | 14.72 | -21.09 | |||||
EBIT, 1 Yr. Growth % | -0.95 | -6.09 | 29.96 | 14.76 | -26.41 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 21.26 | -20.23 | 39.96 | 7.86 | -44.4 | |||||
Net Income, 1 Yr. Growth % | 23.77 | -23.73 | 241.07 | -67.05 | -47.75 | |||||
Normalized Net Income, 1 Yr. Growth % | -2.63 | -8.14 | 25.89 | 23.04 | -29.25 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 23.22 | -24.1 | 33.5 | 9.8 | -48.12 | |||||
Accounts Receivable, 1 Yr. Growth % | 1.13 | 12.56 | -12.71 | 8.31 | -5.79 | |||||
Inventory, 1 Yr. Growth % | 0.82 | -3.55 | -11.02 | 6.84 | 3.11 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -2.72 | -3.03 | -9.86 | 3.5 | 1.16 | |||||
Total Assets, 1 Yr. Growth % | 0.93 | -1.65 | -23.96 | -1.9 | 0.78 | |||||
Tangible Book Value, 1 Yr. Growth % | -14.21 | -1 | -57.91 | -23.54 | 7.22 | |||||
Common Equity, 1 Yr. Growth % | 27.9 | 3.21 | -29.6 | 25.94 | 2.43 | |||||
Cash From Operations, 1 Yr. Growth % | 5.25 | -5.79 | -6.9 | -8.58 | -3.16 | |||||
Capital Expenditures, 1 Yr. Growth % | -3.08 | -4.4 | 20.32 | 14.96 | 6.47 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 60.67 | -19.66 | 2.11 | -28.03 | 37.63 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 54.49 | -19.04 | 2.59 | -26.65 | 31.98 | |||||
Dividend Per Share, 1 Yr. Growth % | 0 | 0 | -38.75 | -5.31 | 5.17 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 5.18 | 0.53 | 9.73 | 10.82 | 3.44 | |||||
Gross Profit, 2 Yr. CAGR % | 4.86 | -0.66 | 8.14 | 14.75 | 6.36 | |||||
EBITDA, 2 Yr. CAGR % | 5.3 | -2.04 | 8.12 | 15.26 | -5.42 | |||||
EBITA, 2 Yr. CAGR % | 5.69 | -2.07 | 8.85 | 18.33 | -6.01 | |||||
EBIT, 2 Yr. CAGR % | 6.39 | -1.44 | 10.01 | 22.13 | -8.1 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 25.65 | -1.65 | -1.8 | 22.87 | -22.56 | |||||
Net Income, 2 Yr. CAGR % | 25.97 | -2.84 | 61.29 | 6.01 | -58.51 | |||||
Normalized Net Income, 2 Yr. CAGR % | 3.99 | -2.82 | 8.92 | 24.46 | -6.71 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 25.1 | -3.29 | -4.96 | 21.07 | -24.53 | |||||
Accounts Receivable, 2 Yr. CAGR % | 3.54 | 6.69 | -0.88 | -2.77 | 1.01 | |||||
Inventory, 2 Yr. CAGR % | 4.64 | -1.39 | -7.36 | -2.5 | 4.96 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | -0.24 | -2.88 | -6.51 | -3.41 | 2.33 | |||||
Total Assets, 2 Yr. CAGR % | 17.69 | -0.37 | -13.52 | -13.63 | -0.57 | |||||
Tangible Book Value, 2 Yr. CAGR % | 15.97 | -7.84 | -35.44 | -43.27 | -9.46 | |||||
Common Equity, 2 Yr. CAGR % | 96.42 | 14.89 | -14.76 | -5.84 | 13.58 | |||||
Cash From Operations, 2 Yr. CAGR % | 0.12 | -0.42 | -6.35 | -7.74 | -5.91 | |||||
Capital Expenditures, 2 Yr. CAGR % | -4.49 | -3.75 | 7.5 | 17.61 | 10.63 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 75.87 | 16.28 | -5.67 | -14.27 | -0.47 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 100.79 | 14.19 | -5.3 | -13.25 | -1.61 | |||||
Dividend Per Share, 2 Yr. CAGR % | 0 | 0 | -21.74 | -23.84 | -0.2 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 4.15 | 3.44 | -4.58 | 7.59 | 8.31 | |||||
Gross Profit, 3 Yr. CAGR % | 3.61 | 2.39 | -4.63 | 8.8 | 10.58 | |||||
EBITDA, 3 Yr. CAGR % | 6.25 | 1.94 | -2.83 | 8.35 | 2.34 | |||||
EBITA, 3 Yr. CAGR % | 7 | 2.05 | -3.32 | 9.87 | 3.38 | |||||
EBIT, 3 Yr. CAGR % | 8.07 | 2.05 | -3.71 | 11.57 | 3.15 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 43.34 | 7.99 | -2.25 | 1.32 | -5.67 | |||||
Net Income, 3 Yr. CAGR % | 55.4 | 6.57 | 47.66 | -5.01 | -16.26 | |||||
Normalized Net Income, 3 Yr. CAGR % | 9.56 | -0.23 | -3.67 | 13.44 | 3.11 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 54.4 | 5.91 | -1.92 | -0.28 | -8.73 | |||||
Accounts Receivable, 3 Yr. CAGR % | 5.9 | 6.46 | -0.21 | 2.09 | -3.79 | |||||
Inventory, 3 Yr. CAGR % | 2.57 | 1.83 | -4.71 | -2.85 | -0.66 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 0.45 | -1.18 | -5.26 | -3.28 | -1.91 | |||||
Total Assets, 3 Yr. CAGR % | 12.57 | 10.86 | -8.95 | -9.81 | -9.07 | |||||
Tangible Book Value, 3 Yr. CAGR % | 3.41 | 10.01 | -29.03 | -31.7 | -29.86 | |||||
Common Equity, 3 Yr. CAGR % | 498.62 | 58.5 | -2.42 | -2.92 | -3.16 | |||||
Cash From Operations, 3 Yr. CAGR % | 6.86 | -1.89 | -2.63 | -7.1 | -6.24 | |||||
Capital Expenditures, 3 Yr. CAGR % | -7.42 | -4.46 | -3.32 | 9.93 | 13.77 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -13.41 | 35.45 | 1.15 | -13.81 | 0.38 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -12.57 | 48.33 | 0.81 | -13.03 | -0.23 | |||||
Dividend Per Share, 3 Yr. CAGR % | 0 | 0 | -15.08 | -16.6 | -15.19 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 7.35 | 4.11 | -0.58 | -0.32 | -1.45 | |||||
Gross Profit, 5 Yr. CAGR % | 9.02 | 3.61 | -0.93 | 0.78 | -0.38 | |||||
EBITDA, 5 Yr. CAGR % | 19.94 | 7 | 1.84 | 1.96 | -4.23 | |||||
EBITA, 5 Yr. CAGR % | 23.35 | 7.96 | 1.89 | 2.31 | -4.41 | |||||
EBIT, 5 Yr. CAGR % | 27.2 | 8.54 | 1.73 | 2.31 | -5.49 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -5.27 | 36.84 | 17.8 | 5.58 | -10.94 | |||||
Net Income, 5 Yr. CAGR % | -7.35 | 36.9 | 57.73 | 6.35 | -11.13 | |||||
Normalized Net Income, 5 Yr. CAGR % | 27.32 | 6.78 | 2.71 | 2.95 | -4.89 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -7.91 | 36.02 | 23.02 | 5.64 | -11.68 | |||||
Accounts Receivable, 5 Yr. CAGR % | 7.73 | 6.24 | 3.14 | 2.67 | 0.28 | |||||
Inventory, 5 Yr. CAGR % | 4.92 | 2.54 | -1.52 | 0.08 | -0.95 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 2.63 | -0.25 | -2.4 | -2.08 | -2.3 | |||||
Total Assets, 5 Yr. CAGR % | 8.52 | 6.01 | 1.3 | 0.32 | -5.69 | |||||
Tangible Book Value, 5 Yr. CAGR % | 9.09 | 1.61 | -14.36 | -15.59 | -21.76 | |||||
Common Equity, 5 Yr. CAGR % | 23.32 | 68.03 | 174.5 | 28.69 | 3.69 | |||||
Cash From Operations, 5 Yr. CAGR % | 26.86 | 4.12 | 1.36 | -4.28 | -3.96 | |||||
Capital Expenditures, 5 Yr. CAGR % | -2.34 | -5.35 | -5.85 | -0.45 | 2.03 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 22.9 | 6.85 | -16.78 | 6.48 | 0.5 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 20.93 | 6.46 | -15.72 | 13.47 | -0.16 | |||||
Dividend Per Share, 5 Yr. CAGR % | 0 | 0 | -9.34 | -10.32 | -9.41 |
- Stock Market
- Equities
- GSK Stock
- Financials GSK plc
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions